TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03486873: A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 3500 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT03486873 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03486873 Rescue Dossier →